New combo therapy aims to shrink tough rectal tumors before surgery
NCT ID NCT01941641
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a two-step approach for high-risk rectal cancer: first, a strong chemotherapy cocktail (FOLFOXIRI), followed by radiation combined with a chemo pill (capecitabine). The goal is to shrink tumors before surgery, making them easier to remove. The study involves 40 adults with aggressive rectal cancer and will measure how well the tumor responds and how safe the treatment is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFOXIRI (combination chemotherapy) and capecitabine (chemotherapy pill)
What this could lead to
If successful, this approach could shrink high-risk rectal tumors before surgery, making them easier to remove and potentially reducing the chance of cancer coming back.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Chemotherapy and radiotherapy have significant side effects, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Clinical Oncology
Hong Kong, Hong Kong